000250 — Sam Chun Dang Pharm Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeLarge CapHigh Flyer

Annual income statement for Sam Chun Dang Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	167,275	177,335	192,669	210,924	231,805
Cost of Revenue
Gross Profit	83,078	89,995	96,966	99,662	109,376
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	183,057	165,111	184,154	208,344	223,389
Operating Profit	-15,782	12,225	8,514	2,580	8,416
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-19,549	8,920	-4,549	11,038	12,518
Provision for Income Taxes
Net Income After Taxes	-10,361	8,832	-4,188	-5,078	12,030
Minority Interest
Net Income Before Extraordinary Items
Net Income	-16,555	5,838	-10,383	-10,916	5,262
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-16,555	5,838	-10,383	-10,916	5,262
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-737	229	-441	-470	210
Dividends per Share